Lifetime cannabis use, Non-affective psychosis
Conditions
Brief summary
Severity of psychotic symptoms
Detailed description
Frequency and quantity of cannabis use by self-reported days of cannabis use per week and amount of use, Cannabis cessation (for current users), defined as no use during the past two weeks (self-reported), Total symptom severity, Symptom response and remission, Global severity of illness, Psychosocial functioning, Neurocognitive functioning, Subjective well-being, Circadian sleep-wake cycle, Subjective sleep quality, Objective sleep evaluation, Metabolomics
Interventions
DRUGEpidyolex placebo
DRUGRisperidon ”Krka”
DRUGRisperidon placebo
Sponsors
Region Hovedstaden
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of psychotic symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency and quantity of cannabis use by self-reported days of cannabis use per week and amount of use, Cannabis cessation (for current users), defined as no use during the past two weeks (self-reported), Total symptom severity, Symptom response and remission, Global severity of illness, Psychosocial functioning, Neurocognitive functioning, Subjective well-being, Circadian sleep-wake cycle, Subjective sleep quality, Objective sleep evaluation, Metabolomics | — |
Countries
Denmark
Outcome results
None listed